Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia

Roberta S. Azevedo, Elias Jabbour, Hagop M Kantarjian, Sravanthi Lavu, Sanam Loghavi, Nitin Jain, Koji Sasaki, Rebecca Garris, Koichi Takahashi, Farhad Ravandi, Nicholas J. Short

Blood blood.2025030498.

https://doi.org/10.1182/blood.2025030498

Published: 2025

Includes: Supplemental data

Journal Articles

Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia

Roberta S. Azevedo, Elias Jabbour, Nitin Jain, Fadi Haddad, Partow Kebriaei, Issa Khouri, Elizabeth Shpall, Richard Champlin, Jayastu Senapati, Eitan Kugler, Omer Karrar, Elias Maroun, Rebecca Garris, Farhad Ravandi, Hagop Kantarjian, Nicholas Short

Blood (2025) 146 (Supplement 1): 549.

https://doi.org/10.1182/blood-2025-549

Published: 2025

Journal Articles

Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

Roberta S. Azevedo, Guillermo Garcia-Manero, Elias Jabbour, Danielle Hammond, Kelly Chien, Tapan Kadia, Steven Kornblau, Farhad Ravandi, Gautam Borthakur, Naveen Pemmaraju, Hyunsoo Hwang, Xuelin Huang, Heather Schneider, Meghan Meyer, Guillermo Montalban-Bravo

Blood (2025) 146 (Supplement 1): 5645.

https://doi.org/10.1182/blood-2025-5645

Published: 2025

Journal Articles

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Blood (2025) 146 (Supplement 1): 3857.

https://doi.org/10.1182/blood-2025-3857

Published: 2025

Journal Articles

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Blood (2025) 146 (Supplement 1): 1726.

https://doi.org/10.1182/blood-2025-1726

Published: 2025

Journal Articles

Characterization of IGHV subgroups and their prognostic relevance in CLL

Daniel Sungchul Choi, Uday Aditya Sarkar, Yue Ren, Yinglu Zhou, Roberta S. Azevedo, James Yoon, Kiyomi Mashima, Fernanda Santos Azevedo, Gordon Saksena, Stacey Fernandes, Paulina Predko, Matthew S Davids, Svitlana Tyekucheva, Jennifer Brown, Inhye Ahn

Blood (2025) 146 (Supplement 1): 3899.

https://doi.org/10.1182/blood-2025-3899

Published: 2025

Journal Articles

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia

Roberta S. Azevedo, Caitlin Rausch, Alexis Geppner, Francisco Vega, Deepa Sampath, Alessandra Ferrajoli, Kelly Chien, Elias Jabbour, Danielle Hammond, Nicholas Short, Koichi Takahashi, Nitin Jain, Jan Burger, Gautam Borthakur, William Wierda, Chitra Hosing, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3653.

https://doi.org/10.1182/blood-2025-3653

Published: 2025

Journal Articles

Fusion transcript dynamics as predictor of optimal molecular response in core-binding factor Acute Myeloid Leukemia

Roberta S. Azevedo, Christopher Manuel, Tapan Kadia, Maro Ohanian, Yesid Alvarado Valero, Wei Qiao, Jayastu Senapati, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur

Blood (2025) 146 (Supplement 1): 1634.

https://doi.org/10.1182/blood-2025-1634

Published: 2025

Journal Articles

Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

Roberta S. Azevedo, Hagop Kantarjian, Jayastu Senapati, Ian Bouligny, Alexandre Bazinet, Wei-Ying Jen, Amin Alousi, Uday Popat, Elizabeth Shpall, Naveen Pemmaraju, Nitin Jain, Eitan Kugler, Cody Belgarde, Elias Jabbour, Guillermo Garcia-Manero, Courtney DiNardo, Naval Daver, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 1630.

https://doi.org/10.1182/blood-2025-1630

Published: 2025

Journal Articles

Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome

Blood (2025) 146 (Supplement 1): 997.

https://doi.org/10.1182/blood-2025-997

Published: 2025

Journal Articles

Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia

Roberta S. Azevedo, Naval Daver, Omer Karrar, Courtney DiNardo, Tapan Kadia, Musa Yilmaz, Gautam Borthakur, Ghayas Issa, Elias Jabbour, Xuelin Huang, Wei Qiao, Regina Abramova, Marina Konopleva, Hagop Kantarjian, Farhad Ravandi, Nicholas Short

Blood (2025) 146 (Supplement 1): 45.

https://doi.org/10.1182/blood-2025-45

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia

Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia

Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Characterization of IGHV subgroups and their prognostic relevance in CLL

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia

Fusion transcript dynamics as predictor of optimal molecular response in core-binding factor Acute Myeloid Leukemia

Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome

Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only